Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TBXA2R | P21731 | 3/20 | 0.75 |
| ▸ | ADRA1A | P35348 | 3/20 | 0.75 |
| ▸ | SLC6A3 | Q01959 | 3/20 | 0.75 |
| ▸ | ABCB11 | O95342 | 3/20 | 0.75 |
| ▸ | ADORA3 | P0DMS8 | 3/20 | 0.75 |
| ▸ | HTR1A | P08908 | 2/20 | 0.75 |
| ▸ | ADRA2A | P08913 | 2/20 | 0.75 |
| ▸ | CHRM1 | P11229 | 2/20 | 0.75 |
| ▸ | DRD1 | P21728 | 2/20 | 0.75 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.75 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.75 |
| ▸ | DRD3 | P35462 | 2/20 | 0.75 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.75 |
| ▸ | ABCB1 | P08183 | 2/20 | 0.75 |
| ▸ | ADRB3 | P13945 | 2/20 | 0.75 |
| ▸ | OPRK1 | P41145 | 2/20 | 0.75 |
| ▸ | SCN5A | Q14524 | 2/20 | 0.75 |
| ▸ | CACNA1C | Q13936 | 2/20 | 0.75 |
| ▸ | KCNK2 | O95069 | 1/20 | 0.75 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.75 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3185862 | 1.00 | TBXA2R (0.75) | TBXA2RADRA1ASLC6A3ABCB11ADORA3 | |
| SCHEMBL31473037 | 1.00 | TBXA2R (0.75) | TBXA2RADRA1ASLC6A3ABCB11ADORA3 | |
| SCHEMBL4990358 | 0.97 | TBXA2R (0.68) | TBXA2RADRA1ASLC6A3ABCB11ADORA3 | |
| SCHEMBL5474815 | 0.96 | ABCB11 (0.67) | TBXA2RADRA1ASLC6A3ABCB11ADORA3 | |
| SCHEMBL7291275 | 0.94 | TBXA2R (0.66) | TBXA2RADRA1ASLC6A3ABCB11ADORA3 | |
| SCHEMBL7286145 | 0.93 | TBXA2R (0.64) | TBXA2RADRA1ASLC6A3ABCB11ADORA3 | |
| SCHEMBL3176152 | 0.92 | TBXA2R (0.61) | TBXA2RADRA1ASLC6A3ABCB11ADORA3 | |
| SCHEMBL5474821 | 0.91 | TBXA2R (0.61) | TBXA2RADRA1ASLC6A3ABCB11ADORA3 | |
| SCHEMBL3186546 | 0.91 | TBXA2R (0.61) | TBXA2RADRA1ASLC6A3ABCB11ADORA3 | |
| SCHEMBL14263736 | 0.91 | TBXA2R (0.61) | TBXA2RADRA1ASLC6A3ABCB11ADORA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080070789-A1 | PROCESS FOR MAKING AMLODIPINE, DERIVATIVES THEREOF, AND PRECURSORS THEREFOR | SLANINA PAVEL | 2008-03-20 | — | — | US | disclosed |
| US-20060167265-A1 | Process for making amlodipine, derivatives thereof, and precursors therefor | PETERS THEODORUS H | 2006-07-27 | — | — | US | disclosed |
| EP-1577298-A1 | Process for determining the purity of amlodipine | Bioorganics B.V. (NL) | 2005-09-21 | — | — | EP | disclosed |
| US-20050137405-A1 | Process for making amlodipine, derivatives thereof, and precursors therefor | PETERS THEODORUS H A (NL) | 2005-06-23 | — | — | US | disclosed |
| US-6858738-B2 | Process for making amlodipine, derivatives thereof, and precursors therefor | SYNTHON BV (NL) | 2005-02-22 | — | — | US | disclosed |
| US-6653481-B2 | Used as calcium channel blockers | SYNTHON BV (NL) | 2003-11-25 | — | — | US | disclosed |
| US-20020143046-A1 | Process for making amlodipine, derivatives therof, and precursors therefor | SYNTHON IP INC. | 2002-10-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060167265-A1 | Process for making amlodipine, derivatives thereof, and precursors therefor | CYP4A11, CYP4F11, CACNA1D | TBXA2R 2231/4885ADRA1A 1686/4885SLC6A3 3639/4885 |
| US-20050137405-A1 | Process for making amlodipine, derivatives thereof, and precursors therefor | CACNA1D, CACNA1S, CACNA1C | TBXA2R 245/4885ADRA1A 199/4885SLC6A3 4429/4885 |
| US-20020143046-A1 | Process for making amlodipine, derivatives therof, and precursors therefor | CACNA1D, CACNA1F, CACNA1S | TBXA2R 173/4885ADRA1A 163/4885SLC6A3 4533/4885 |
| US-20080070789-A1 | PROCESS FOR MAKING AMLODIPINE, DERIVATIVES THEREOF, AND PRECURSORS THEREFOR | CACNA1D, CACNA1F, CYP51A1 | TBXA2R 737/4885ADRA1A 711/4885SLC6A3 3562/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.